Shots:
- The partnership will utilize Novogene’s molecular diagnostics capabilities to expand patient identification by NGS in China for supporting the development of Hummingbird’s HMBD-001 which is expected to enter P-I study in 2021 to treat NRG1-fusion driven cancers
- The partnership focuses on validation and expansion of clinical-grade testing for NRG1 fusions in patient populations with selected solid tumors
- The pre-clinical studies showed that the therapy potently inhibits the formation of heterodimers, blocking the activation of signaling pathway and prevents tumor growth
Click here to read full press release/ article | Ref: PR Newswire | Image: PR Newswire
The post Hummingbird Collaborates with Novogene to Expand Precision Therapy Testing for NRG1-Fusion Driven Cancers in China first appeared on PharmaShots.
